Paris, 18 June 2010 – NYSE Euronext today announced the admission of IntegraGen, a pioneer in the development of molecular diagnostic tools, to NYSE Alternext.
IntegraGen is a major contender in clinical genomics, where it is developing a line of products and services for genetic diagnostic, the most dynamic segment of the in-vitro diagnostics market. IntegraGen (ticker symbol: ALINT) was admitted to NYSE Alternext by direct listing of the 3,771,471 existing shares making up its capital. This followed the private placement with qualified investors of 800,149 new shares at a subscription price of €8.40 each, for a total €6.7 million. Market capitalization of IntegraGen on the date of admission amounted to €31.7 million.